Y-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Beats Expectations By $0.20 EPS

Key Points

• Y-mAbs Therapeutics reported an earnings per share (EPS) of ($0.07), exceeding analysts' estimates by $0.20, along with quarterly revenue of $19.52 million surpassing the expected $18.40 million.
• Institutional ownership is significant, with hedge funds holding 70.85% of the stock, including a notable 869.3% increase in stake by AQR Capital Management in Q1.
• Stock ratings have been downgraded recently, with several analysts lowering their price targets to $8.60, indicating a general sentiment shift towards a more cautious outlook on the stock.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) released its earnings results on Friday. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20, Zacks reports. The business had revenue of $19.52 million for the quarter, compared to the consensus estimate of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 31.84% and a negative return on equity of 30.59%.

Y-mAbs Therapeutics Stock Down 0.1%

Shares of Y-mAbs Therapeutics stock opened at $8.51 on Friday. The stock has a market capitalization of $385.33 million, a P/E ratio of -17.02 and a beta of 0.57. The company has a 50-day simple moving average of $4.94 and a 200 day simple moving average of $4.94. Y-mAbs Therapeutics has a 12-month low of $3.55 and a 12-month high of $16.11.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A hedge fund recently raised its stake in Y-mAbs Therapeutics stock. AQR Capital Management LLC raised its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 869.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 164,788 shares of the company's stock after acquiring an additional 147,788 shares during the quarter. AQR Capital Management LLC owned about 0.36% of Y-mAbs Therapeutics worth $730,000 as of its most recent filing with the Securities and Exchange Commission. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Oppenheimer lowered shares of Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Tuesday. HC Wainwright lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and dropped their price objective for the company from $11.00 to $8.60 in a research note on Wednesday. Canaccord Genuity Group downgraded shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and decreased their target price for the stock from $26.00 to $8.60 in a research report on Tuesday. Truist Financial set a $8.60 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald set a $8.60 target price on shares of Y-mAbs Therapeutics and gave the stock a "neutral" rating in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $11.16.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.